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AbstrAct
Introduction Total hip arthroplasty (THA) and total knee 
arthroplasty (TKA) are highly successful treatment modalities 
for advanced osteoarthritis. However, prolonged wound 
leakage after arthroplasty is linked to prosthetic joint infection 
(PJI), which is a potentially devastating complication. On the 
one hand, wound leakage is reported as a risk factor for PJI 
with a leaking wound acting as a porte d’entrée for micro-
organisms. On the other hand, prolonged wound leakage can 
be a symptom of PJI. Literature addressing prolonged wound 
leakage is scarce, contradictory and of poor methodological 
quality. Hence, treatment of prolonged wound leakage varies 
considerably with both non-surgical and surgical treatment 
modalities. There is a definite need for evidence concerning 
the best way to treat prolonged wound leakage after joint 
arthroplasty.
Methods and analysis A prospective nationwide 
randomised controlled trial will be conducted in 35 
hospitals in the Netherlands. The goal is to include 388 
patients with persistent wound leakage 9–10 days after 
THA or TKA. These patients will be randomly allocated to 
non-surgical treatment (pressure bandages, (bed) rest 
and wound care) or surgical treatment (debridement, 
antibiotics and implant retention (DAIR)). DAIR will also 
be performed on all non-surgically treated patients with 
persistent wound leakage at day 16–17 after index 
surgery, regardless of amount of wound leakage, other 
clinical parameters or C reactive protein. Clinical data are 
entered into a web-based database. Patients are asked 
to fill in questionnaires about disease-specific outcomes, 
quality of life and cost effectiveness at 3, 6 and 12 months 
after surgery. Primary outcome is the number of revision 
surgeries due to infection within a year of arthroplasty.
Ethics and dissemination The Review Board of each 
participating hospital has approved the local feasibility. The 
results will be published in peer-reviewed scientific journals.
trial registration number NTR5960;Pre-results. 
IntroductIon 
Osteoarthritis (OA) is the most common 
joint disorder worldwide and is recognised 
as a substantial source of disability.1 Total hip 
arthroplasty (THA) and total knee arthro-
plasty (TKA) are highly successful and widely 
accepted surgical treatment modalities for 
advanced OA of the hip and knee. In 2015, 
28 798 THAs and 27 082 TKAs were performed 
in the Netherlands2 and 310 800 THAs and 
693 400 TKAs were performed in USA in 
2010.3 4 The demand for joint arthroplasty 
continues to rise due to an ageing population 
and changing thresholds for surgery and is 
expected to keep increasing in the coming 
decades.5 Unfortunately, this results in higher 
absolute numbers of complications after joint 
arthroplasty. One of the most serious and 
potentially devastating complications is pros-
thetic joint infection (PJI).
Persistent wound leakage after primary 
THA or TKA is associated with PJI. Wound 
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Protocol
strengths and limitations of this study
 ► This nationwide study is the first randomised 
controlled trial to compare outcomes of non-surgical 
treatment and surgical treatment in patients with 
prolonged wound leakage after total hip and knee 
arthroplasty.
 ► This study is an initiative of the Netherlands 
Orthopaedic Association. The optimal treatment 
for persistent wound leakage is unknown and is 
considered an important knowledge gap. This is why 
numerous Dutch hospitals participate, allowing for 
inclusion of a large number of patients.
 ► Since literature addressing wound leakage is 
scarce, there is no evidence for the optimal timing 
of debridement,  antibiotics and implant retention 
(DAIR). Therefore, timing of the early intervention 
(DAIR at day 9–10) is based on consensus instead 
of evidence.
 ► Orthopaedic surgeons may be reluctant to randomise 
patients in case of minimal wound leakage (LEAK 
class 1). This may induce biased results.
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leakage is induced in the postoperative phase by an inflam-
matory response.6 Conversely, surgical wounds may also 
show prolonged leakage for other reasons (hematoma, 
seroma or fatty necrosis) and take longer to heal without 
development of a PJI. Prolonged wound leakage is a risk 
factor for PJI as a leaking wound can be a porte d’entrée 
for micro-organisms (retrograde infection pathway).7 
Bacteria can rapidly form a biofilm on the metal surface 
of the prosthesis, thereby decreasing the effectiveness of 
the host defence and antimicrobial therapy. It is estimated 
that in the Netherlands about 2200 patients annually (4% 
of ±55 000 THA/TKA) have wound leakage at day 9 after 
index surgery.2 6 As PJI is a serious and potentially devas-
tating complication, prolonged wound leakage should 
be considered as potentially imminent PJI, with fluid 
production as a symptom or a risk factor for infection.
PJI has an enormous impact on patients as well as society, 
as it often results in septic revision surgery, requiring 
removal of the infected implant to eradicate the infection 
and hopefully allowing subsequent reimplantation. This 
septic revision surgery is accompanied by a large negative 
impact on the quality of life of patients and high health-
care costs (± €30 000 per patient with PJI in UK),8 due 
to extended hospital stays, costly surgical procedures, 
prolonged use of antibiotics and impaired function of 
the hip or knee. The Dutch Arthroplasty Register reports 
a total of 3809 THA and 2667 TKA revision surgeries 
performed in 2015.2 Revision surgery within 1 year of 
index surgery was necessary in more than 600 patients 
and at least 30% of these were PJI-related.2
Persistent wound leakage can be treated by non-sur-
gical and surgical treatment modalities. Non-surgical 
treatment can consist of relative rest (no exercise and 
bed rest), pressure bandages (hip spica or knee pressure 
bandage) and wound care with sterile bandages. Hospital 
admission can be required. Surgical treatment typically 
consists of debridement, antibiotics and implant reten-
tion (DAIR).9 10 A DAIR procedure is meant to clean 
the prosthesis and wound, including breaking down the 
biofilm, in order to treat the infection and render further 
infection treatment unnecessary. Treatment of persistent 
wound leakage varies considerably among Dutch hospi-
tals, as confirmed recently by a nationwide question-
naire-based survey regarding both non-surgical and 
surgical treatment modalities.11 However, these modali-
ties have never been studied comparatively.
Several authors have investigated the effect of DAIR 
for treatment of persistent wound leakage and reported 
various results and/or made (opinion-based) statements, 
generally in favour of early DAIR.6 10–15 The most recent 
PJI consensus meeting suggests five to seven days of wound 
leakage as the threshold to perform DAIR, but there is no 
solid evidence for this statement. Therefore, the optimal 
timing of DAIR is yet to be established, which could imply 
that either overtreatment or undertreatment may occur. 
As the treatment decision-making process is generally 
relatively easy in patients with severe wound leakage and a 
high suspicion of infection, this study particularly aims to 
provide evidence for the best treatment of patients with a 
low suspicion of infection.
As early DAIR is hypothesised to be helpful in treating 
or preventing infection and salvaging the implant, 
the objective of this study is to determine the clinical 
outcome and cost effectiveness of early surgical inter-
vention (DAIR at day 9–10 after index procedure) versus 
non-surgical treatment in patients with prolonged wound 
leakage after primary THA/TKA. In addition, the impact 
on disease-specific and general health-related quality of 
life will be determined. Our hypothesis, based on the 
scarce literature mentioned above, is that performing 
a DAIR at day 9–10 will result in a 50% reduction rate 
of revision surgery for PJI up to one year after primary 
THA/TKA compared with non-surgical treatment.
MEthods And dEsIgn
study design and procedure
A prospective nationwide multicentre randomised 
controlled trial (RCT) will be conducted. The study 
will be carried out in 35 hospitals throughout the Neth-
erlands. All patients aged 18 or older and scheduled to 
undergo primary THA/TKA in the participating hospi-
tals will receive written and oral information about 
the LEakage After primary Knee and hip arthroplasty 
(LEAK) study. Patients with persistent wound leakage at 
day 5–7 after index surgery will be monitored carefully 
and receive non-surgical treatment. Clinical examination, 
wound classification and C reactive protein (CRP) will be 
carried out at day 5–7 and day 9–10. In case of persistent 
leakage at day 9–10 after index surgery, the patient will 
be included in the study (after signing the informed 
consent form) and randomised to either surgical treat-
ment (DAIR at 9–10) or continued non-surgical treat-
ment. Patients allocated to the non-surgical treatment 
group with persistent wound leakage at day 16–17 after 
index surgery will also be subjected to a DAIR, regardless 
of amount of wound leakage, other clinical parameters 
or CRP. Patients in the non-surgical treatment group with 
clear signs of infection (defined as temperature >38.5°C, 
increasing wound leakage, redness, pain and increasing 
CRP (>25% compared with day 9–10)) earlier than day 
16–17 will receive surgical treatment at that time point. 
Patients with clear signs of infection earlier than or at day 
nine after index surgery will receive surgical treatment 
without randomisation (see online supplementary figure 
1). The extended version of the study protocol flowchart 
is enclosed in online supplementary figure 2.
Randomisation will be performed by a web-based 
system (developed by Interactive Studios, Rosmalen, 
The Netherlands), based on the software Apache and 
MySQL. Each participating hospital receives an indi-
vidual login in order to register and randomise patients. 
A two-day time window for randomisation (day 9–10) is 
chosen to facilitate implementation of the protocol, as 
some patients undergo surgery on days of the week that 
result in follow-up moments in the weekend, which may 
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hamper inclusion. Since there is no uniform classification 
for wound leakage, experts in the field of PJI (the LEAK 
study group) developed a wound leakage classification 
system based on amount of wound leakage, called the 
LEAK-classification, consisting of four classes: LEAK class 
0: dry wound, LEAK class 1: mild wound leakage (<2×2 cm 
in gauze per 24 hours), LEAK class 2: moderate wound 
leakage (>2×2 cm in gauze and no need for >1 absorbent 
gauze exchange per 24 hours) and LEAK class 3: severe 
wound leakage (need for >1 absorbent gauze exchange 
per 24 hours). Due to the nature of the study, patients 
and surgeons cannot be blinded. Data analyses will be 
performed blinded.
Inclusion and exclusion criteria
All patients aged 18 or older with persistent wound 
leakage at day 9–10 after primary THA/TKA surgery are 
eligible for inclusion and subsequent randomisation for 
the surgical treatment (DAIR at day 9–10) or continued 
non-surgical treatment. Exclusion criteria are mental or 
physical disability to fulfil study requirements and insuffi-
cient command of the Dutch language.
surgical treatment
The surgical treatment consists of DAIR at day 9–10. DAIR 
consists of opening the wound and obtaining one culture 
from the intra-articular synovial fluid deep to the fascia 
and at least four deep-tissue cultures: two synovial and at 
least two around the components of the joint prosthesis. 
Empirical antimicrobial treatment in accordance with 
the local protocol is started after obtaining cultures and 
excising haematoma and necrosis. Mobile parts (eg, tibial 
insert, femoral head and acetabular liner) are exchanged 
to make room for optimal debridement. The wound is 
extensively debrided and lavaged using 3–6 L of saline 
(alternative is a povidone iodine solution or chlorhexi-
dine solution). Mechanical scrubbing of the visible pros-
thetic parts is advised.
non-surgical treatment
The non-surgical treatment consists of relative rest (stop 
exercise and start bed rest), pressure bandages (hip 
spica or knee pressure bandage) and wound care with 
sterile bandages. The non-surgical treatment is option-
ally carried out in a hospital admission setting. Patients 
in the non-surgical treatment group do not receive anti-
microbial treatment. In non-surgically treated patients 
clinical examination, wound classification and CRP are 
performed at day 16–17 after index surgery. A DAIR will 
also be performed on all patients with persistent wound 
leakage at day 16–17 after index surgery, regardless of 
amount of wound leakage, other clinical parameters or 
CRP.
outcome measures
Primary outcome is the percentage of reoperations for 
PJI within one year of index surgery. Reoperation refers 
to any kind of septic revision surgery (one or two stage, 
Girdlestone, arthrodesis or amputation). In addition, any 
other PJI treatment modalities are recorded (repeated 
DAIR, start of suppressive antimicrobial treatment or 
watchful neglect).
Secondary outcomes are the impact of surgical 
treatment compared with non-surgical treatment on 
disease-specific outcome and general health-related 
quality of life and the economic evaluation (cost-effec-
tiveness and cost utility) of the surgical and non-surgical 
treatment. Self-reported questionnaires will be used to 
measure these outcome parameters. All questionnaires 
used are recommended by the Netherlands Orthopaedic 
Association as a quality assessment tool of orthopaedic 
care and are included in the standard Patient  Reported 
Outcome Measure (PROM) list for both THA and TKA 
patients. Randomised patients will fill in these question-
naires 3, 6 and 12 months after index surgery.
Clinical data
Clinical data will be recorded from randomised patients, 
patients who undergo surgical treatment earlier or at day 
nine because of clear signs of infection and patients with 
persistent wound leakage at day 5–7 but a dry wound at 
day 9–10 after index surgery. Data are recorded in the 
web-based database. Demographic characteristics, body 
mass index, American Society of Anesthesiologists score, 
immunosuppressant medication, diabetes and anticoagu-
lants will be recorded. Further data include information 
about the index surgery, reoperation for PJI, postopera-
tive complications, clinical signs of infection, use of anti-
biotics and measurement of CRP. For those patients who 
are allocated to surgical treatment, details of the DAIR 
procedure and culture results will be recorded. In case 
of repeated DAIR procedures, the information will also 
be specified in the database. The clinical data are filled 
in by a physician of the participating hospital, to preserve 
doctor-patient confidentiality.
Disease-specific outcome and general health-related quality of life
Questionnaires that will be used to measure disease-spe-
cific outcome are the Hip and Knee disability and Osteo-
arthritis Outcome Score—physical function short form 
(HOOS-PS/KOOS-PS)16 17 and the Oxford Hip and 
Knee Score (OHS/OKS).18 19 General health-related 
quality of life will be measured by the EuroQol-5D-5L 
(EQ-5D-5L).20 21
The HOOS-PS and KOOS-PS are disease-specific 
PROMs derived from the original HOOS and KOOS ques-
tionnaires. These questionnaires inform after hip or knee 
disability in patients with osteoarthritis. The HOOS-PS 
consists of five items assessing physical function with inter-
val-level properties. Questions are answered using a Likert 
scale, in which a higher score reflects more symptoms and 
limitations. The KOOS-PS contains seven items. Questions 
are answered using a Likert scale, with higher scores indi-
cating more limitations in physical functioning. The raw 
scores are converted to a 0-to-100 scale with 100 as the best 
outcome. The Dutch language versions of the HOOS-PS 
and KOOS-PS are considered reliable and valid.16 17
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The OHS and OKS are disease-specific PROMs. These 
questionnaires consist of 12 questions covering function 
and pain associated with the hip or knee. Questions are 
answered using a Likert scale. Scoring involves summating 
the total for each item to produce a final score between 
0 and 48, with a higher score indicating greater disability. 
The questionnaires are considered reliable, valid and 
sensitive to clinically important changes over time and are 
available in the Dutch language.18 19
The EQ-5D-5L is a widely used and valid generic instru-
ment to measure general health-related quality of life and 
is validated in the Dutch language.20 21 The EQ-5D-5L 
consists of two parts. The first part consists of five dimen-
sions: mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression. Each dimension is scored 
using a Likert scale. The combined scores of these five 
dimensions are converted to the EQ-5D index score.21 
The second part consists of a 20 cm visual analogue scale 
(EQ-VAS) that has endpoints labelled ‘best imaginable 
health state’ and ‘worst imaginable health state’ anchored 
at 100 and 0, respectively. Respondents are asked to indi-
cate how they rate their own health by writing down the 
number representing the point on the EQ-VAS which 
best represents their own health on that day.20 21 The 
EQ-5D-5L is embedded in this study protocol, as it is espe-
cially useful in combination with the economic evaluation 
that will be conducted in order to calculate utilities.
Economic evaluation
The primary aim of the economic evaluation will be to esti-
mate the societal costs of the strategy to perform a DAIR 
at day 9–10 and compare this to the costs of a continued 
non-surgical treatment strategy. Secondary aim will be to 
estimate the cost effectiveness of the surgical treatment 
compared with non-surgical treatment (from a societal 
perspective), based on the primary measure of effective-
ness (number of infections prevented).
Cost effectiveness analyses (CEA) and cost utility anal-
yses (CUA) based on EQ-5D-5L-defined utilities will be 
performed to describe the financial consequences of 
both surgical and non-surgical treatment. All items of 
resource use will be collected at the patient level, using 
case record forms and the patient questionnaires Medical 
Consumption Questionnaire (iMCQ) and Productivity 
Cost Questionnaire (iPCQ). The iMCQ is a generic instru-
ment for measuring medical costs. The questionnaire 
includes 31 questions related to frequently occurring 
contacts with healthcare providers.22 The iPCQ is a stan-
dardised generic instrument for measuring and valuing 
productivity losses. The questionnaire includes 12 ques-
tions divided into three modules measuring productivity 
losses of paid work due to absenteeism, presenteeism and 
productivity losses related to unpaid work.23 24
The CEA and CUA integrate two quantities: the addi-
tional costs (or savings) of surgical treatment compared 
with non-surgical treatment and the additional health 
benefits. Based on these two quantities the incremental 
cost effectiveness ratio is calculated, which is the difference 
in costs divided by the difference in effects. Results of 
the CEA will display the additional costs or savings with 
surgical treatment in order to prevent one additional 
patient with an infection compared with non-surgical 
treatment. In the CUA, the impact on quality adjusted 
life year (QALY) will rely on the results based on the 
EQ-5D-5L. Results of the CUA will display the additional 
costs or savings with surgical treatment in order to gain 
one QALY compared with non-surgical treatment.
Healthcare will be valued using standard prices,25 with 
time and travel costs included in the CEA and CUA. 
Productivity losses will be valued using both the fric-
tion-cost method (primary analysis) and the human-cap-
ital method (sensitivity analysis). The time horizon will 
be 12 months; therefore, the analysis will not include 
discounting of costs and effects. Bootstrap resampling 
will be performed on the cost as well as on the cost and 
effect pairs in order to calculate CIs. Cost effectiveness 
acceptability curves will be plotted to estimate the proba-
bility of surgical treatment being more cost-effective than 
non-surgical treatment, for different amounts of money 
that a decision-maker may be willing to pay for one addi-
tional unit of effect (infection avoided or QALY).
sample size
The power analysis is based on the assumption that 20% 
of patients with persistent wound leakage at day 9–10 
will necessitate revision surgery. It is hypothesised that 
surgical treatment (DAIR at day 9–10) will prevent 50% 
of PJIs and consequently revision surgery compared 
with non-surgical treatment. In order to detect this 50% 
reduction with 80% power at a significance level of 0.05, 
155 patients are required in the surgical treatment group 
and 155 in the non-surgical treatment group. With an 
expected dropout rate of approximately 20%, a sample 
size of 194 patients per group is needed, making up a 
total required patient group of 388 patients.
statistical analysis
Descriptive statistics will be used to analyse patient char-
acteristics. The primary outcome of the study is revision 
surgery for PJI within one year of index surgery (a binary 
variable). At least two measurements will be collected, 
namely at the time of randomisation (at day 9–10) and 
one year after index surgery. The dependency of the 
measurements within the patient is our focal interest. To 
take into account other dependencies (eg, the hospital in 
which the patient is treated), a multilevel logistic regres-
sion model with three levels will be used to analyse the 
data. The three levels are hospitals, patients and measure-
ments. As this study is designed as an RCT, every patient 
can be classified as a case (surgical treatment) or control 
(non-surgical treatment). The effect of the intervention 
will be controlled for relevant covariates such as age and 
gender. Intention-to-treat analyses will be conducted. 
Subanalyses will be performed for patients with wound 
leakage after THA and TKA separately, to gain insight 
into the effectiveness of the intervention. Moreover, 
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subanalyses will be performed within both treatment 
groups to distinguish between patients who initially 
received non-surgical treatment but were treated with 
a DAIR at day 16–17 versus patients who only received 
non-surgical treatment (non-surgical treatment group) 
and between patients who received one DAIR versus two 
DAIRs (surgical treatment group).
For all analyses, a one-tailed significant level of P<0.05 
is considered to be statistically significant. All statistical 
analyses will be performed using SPSS V.24.0 for Windows 
(IBM, Armonk, New York, USA).
EthIcs And dIssEMInAtIon
The Review Board of each participating hospital has exam-
ined and approved the local feasibility. The study will be 
conducted according to the principles of the Medical 
Research Involving Human Subjects Act (WMO), the Good 
Clinical Practice standard (GCP) and the Declaration of 
Helsinki. Eligible patients will be informed about the study 
and will sign an informed consent form in order to partici-
pate. Serious adverse events will be recorded and reported 
to an independent data and safety monitoring board. 
Auditing and monitoring will be carried out throughout the 
duration of the study. We began recruitment in February 
2017 and expect to have completed recruitment by August 
2018 and completed data collection by August 2019. The 
results of this study will be published in international 
peer-reviewed scientific journals.
dIscussIon
Wound leakage is associated with PJI, with fluid produc-
tion as a symptom or a risk factor for infection. With 
increasing numbers of joint arthroplasties worldwide, 
the number of PJIs is rising as well. Without an evidence-
based guideline, there is huge variation in clinical prac-
tice regarding the treatment of persistent wound leakage 
in the Netherlands and abroad, with both non-surgical 
and surgical treatment modalities being used (submitted 
data). The most recent PJI consensus meeting suggests 
5–7 days of wound leakage as the threshold to perform 
a DAIR-procedure.26 However, this statement remains 
unproven and comparative studies on early surgical inter-
vention (DAIR) versus non-surgical treatment are lacking. 
There is a need for an unambiguous clinical guideline to 
treat persistent wound leakage.
Objective of the LEAK study is to determine the 
outcome of surgical treatment (DAIR at day 9–10) 
versus non-surgical treatment. Performing surgical 
treatment at day 9–10 is a compromise between the 
recommendation of the most recent PJI meeting and 
usual clinical practice in the Netherlands.26 In prepa-
ration of designing this RCT, we performed a survey 
among Dutch orthopaedic surgeons to evaluate current 
Dutch orthopaedic care for persistent wound leakage 
after joint arthroplasty. As only 17.2% of Dutch ortho-
paedic surgeons started surgical treatment after 5–7 
days of wound leakage and 44.1% after 10 days of wound 
leakage,11 we decided to perform surgical treatment at 
day 9–10 after joint arthroplasty.
Based on the scarce literature available, the conserva-
tive assumption is that wound leakage is associated with 
revision for PJI in 20% of cases, and it is hypothesised 
that surgical treatment (DAIR on day 9–10) will reduce 
this to a 10% revision rate for PJI, that is, a 50% reduc-
tion within one year of primary THA/TKA compared 
with continued non-surgical treatment. It is hypothe-
sised that in the long run (more than one year) even 
a larger reduction can be achieved, as many cases of 
PJI are caused by lower-virulence pathogens, and PJI 
within 2–5 years is generally considered as related to 
the index surgery. In this study, participating patients 
will be followed up for one year. This follow-up length 
is chosen because of restrictions from the subsidiary 
agency. Additional follow-up will be done through the 
Dutch National Registry for Orthopaedic Implants 
(LROI).
If the hypothesis as formulated in the LEAK study is 
confirmed, this will offer a firm body of evidence for the 
development of a guideline for treatment of prolonged 
wound leakage, eventually resulting in a lower percentage 
of PJIs and therefore a significant improvement of phys-
ical functioning and health-related quality of life for 
patients with prolonged wound leakage. Moreover, from an 
economic perspective, it will lead to significant cost savings 
in orthopaedic healthcare. It is estimated that in the Neth-
erlands about 2200 patients annually (4% of ±55 000 THA/
TKA) have wound leakage at day 9–10.2 6 It is hypothesised 
that the number of patients needing revision surgery for 
PJI with non-surgical treatment will be 200–400 compared 
with 100–200 with surgical treatment at day 9–10 after 
index surgery. Costs of standard treatment are difficult to 
estimate due to large variations in current clinical practices. 
Costs of the study intervention (DAIR) are about €3000. 
Additional savings include the avoided reinterventions, 
which amount to approximately €30 000 per procedure. 
The hypothesised reduction in orthopaedic healthcare 
costs by implementing the LEAK study protocol is €300 000 
per year nationwide. This reduction in healthcare costs will 
be even greater considering the fact that PJI may develop 
later than one year after index surgery. Furthermore, it is 
hypothesised that performing surgical treatment (DAIR 
at day 9–10) can reduce the productivity loss associated 
with reoperations and can reduce the costs associated with 
prolonged home-care and informal care provided by rela-
tives, which come in addition to the healthcare costs.
During the design of the LEAK study, the project 
team discussed using a non-inferiority design. This was 
discarded, as it is estimated that the effect of surgical 
treatment is sufficiently large to provide evidence for the 
superiority of performing an early DAIR procedure.
In conclusion, clinical practice for the treatment 
of persistent wound leakage varies considerably. The 
dilemma is that not all postoperative prolonged wound 
leakages are a proxy for PJI, but delaying surgical 
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treatment for too long may result in undertreatment 
and development of a PJI. At the present time, the liter-
ature shows no evidence for superiority of surgical over 
non-surgical treatment. The results of the current study 
will contribute to development of evidence-based guide-
lines on the optimal treatment and treatment timing of 
persistent wound leakage after THA and TKA.
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